NORWOOD, Mass.--(BUSINESS WIRE)--Aspect Medical Systems, Inc. (NASDAQ: ASPM) Vice President of Medical Affairs, Scott Kelley, MD, presented comments today at an open public hearing conducted in Washington, DC as part of a Food and Drug Administration (FDA) meeting about the preclinical neurotoxicity of anesthetic drug products. The meeting was convened by the Anesthetic and Life Support Drugs Advisory Committee of the FDA to review preclinical presentations regarding studies conducted in juvenile animals that indicate neurodegenerative effects from exposure to anesthetic drugs. Meeting participants discussed these presentations and their implications for the practice of anesthesia and the need for further preclinical and clinical studies. Dr. Kelley’s comments and presentation are available for viewing on the Aspect Medical Systems Web site at http://www.aspectmedical.com/. More information about the FDA advisory committee is available at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4285b1-01.pdf.
